Introduction
cations from fistulae. The procedure is monitored using transrectal ultrasonography (TRUS) to confirm the posCryotherapy is not new and was probably first used to treat skin tumours by Arnott almost 150 years ago [1] .
ition of the guidewires and subsequently the probes, and to monitor the size of the iceball created and avoid The advent of insulated probes and more sophisticated machines capable of delivering liquid nitrogen, as well damage to adjacent structures. The rim of the iceball, as seen on TRUS, is an interface between hyperechoic as the use of ultrasonographic techniques [2, 3] for controlling the freezing process, has allowed the more normal prostate and the hypoechoic iceball, and is used to indicate adequate cytodestruction. widespread application of the technique to treat visceral tumours. Cryotherapy is now widely used for the treat-
The ultrasonographic characteristics of frozen prostate have been described [11] but there has been no attempt ment of primary [4] and secondary liver tumours [5, 6] and prostate cancer [7] . Prostate cryosurgery has been to define the sensitivity of prostate cancer to cryoablative therapy, other than in clinical trials. Of particular conused at open operation to treat prostate cancer and has achieved results equivalent to other local treatment cern with this technique is the attainment of adequate destruction of the tumour posteriorly, without injuring modalities, with equally good long-term survival [8] [9] [10] . However, the procedure fell into disrepute because of the the rectum. The aim of the present study was to define the in vivo high incidence of complications, including the formation of fistulae.
sensitivities of prostate cancer cells in a mouse model to cryotherapy and to define the minimum temperature The advent of transrectal ultrasound-guided percutaneous radical cryosurgical ablation of the prostate by required to cause adequate cytodestruction and prevent tumour recurrence. Onik et al. [7] has allowed the use of multiple, synchronous, small diameter (3 mm) percutaneous insulated probes to deliver the low temperature and to monitor calf serum, 7.5% sodium bicarbonate and 200 mm of l-glutamine, in 5% CO 2 , until confluent (Gibco BRL, the area calculated. Those mice with tumours that grew markedly were killed and the tumours recovered and Life Technologies Inc, Grand Island, NY, USA). Twentyfive male 8-10-week-old nu/nu mice (ANSTO, Lucas fixed in 70% ethanol. A standard haematoxylin and eosin stain was used to verify histologically any tumour Heights, Australia) were subcutaneously injected with 5×105 cells of PC-3. After 3 weeks the tumour xenogrecurrence. Those mice that developed skin necrosis or growth of tumours during the next 2 months were also rafts had grown to a mean area of 60.4 mm2 (sem 5.7). The mice were anaesthetized by an intraperitoneal killed (Group 1), which comprised 15 mice. At the end of 3 months, seven mice were alive and tumour-free injection with Hypnorm (100 mL of a 10% solution; Jansen, Pharmacentica) and midazolam 100 mg (Roche (Group 2). Fisher's exact test was used to determine significant Products, Basel, Switzerland). The subcutaneous xenograft was exposed through a skin incision and a 3 mm differences in the recurrence rates of each tumour group and Student's t-test was used to determine significant cryotherapy probe (Cryotech, UK) applied to the tumour to freeze it. The Cryotec 3000 system (Cryotech, UK) differences in pre-treatment tumour size between the groups. was used to deliver the liquid nitrogen to the probe. An insulated thermocouple was placed with the tip at the part of the tumour most remote from the cryoprobe Results (Fig. 1) . The tumours were frozen to temperatures ranging from 0°C to −40°C at this edge, using a single
The tumour temperatures recorded for the 15 mice in Group 1 ranged from 0°to −15°C. Histological examinfreeze/thaw cycle. The tumours were then thawed and the skin closed over the tumour with a 5-0 absorbable ation confirmed obvious tumour recurrence in eight mice. The other seven mice had histological evidence of suture. The mice were recovered and actively rewarmed by an infrared lamp. Three mice died from complications necrosis but not of tumour, although this may represent sampling error, as these tumours had grown. The caused by anaesthesia.
The bidirectional diameters of the tumours were meastumour temperatures recorded for the seven mice in Group 2 ranged from −15°to −40°C. ured with vernier calipers twice weekly for 3 weeks and
The pre-treatment mean area of the tumours for all 25 mice measured 3 weeks after innoculation was 60 mm2 (sem 6). Three weeks after cryotherapy the mean tumour area in Group 1 was 97 mm2 (sem 14) and in Group 2 was 32 mm2 (sem 7). Figure 2 shows individual tumour size at 3 weeks for each group. Figure 3 shows the change in mean size with time for the two groups . There was no significant difference between the groups in mean pre-treatment size.
All recurrences were confirmed histologically. No recurrences from a group of seven animals compared with eight recurrences from a group of 15 is marginally significantly different by Fisher's exact test (P=0.083).
Discussion
The viability of tumour cells following in vitro freezing has been investigated [12,13] but temperatures required for in vitro cellular destruction are much lower than those which are effective in vivo. In vitro cell death is thought to be secondary to the formation of ice crystals and to osmotic effects [14] but the in vivo cytodestructive effect of single freeze/thaw cycle cryotherapy in a vascular bed such as liver or prostate is thought to be principally caused by ischaemia from the vascular effects of freezing [15] . It is possible that it is easier to destroy prostate cancer in the relatively well-vascularized prostate than in the subcutaneous site of this mouse model. The results of this study are novel and potentially the present study suggests that temperatures considerably less than 0°C are required to achieve ablation of human prostate cancer cells.
The present study demonstrates that, in this in vivo model of prostate cryosurgery, the temperature required to prevent tumour recurrence was <−15°C. We would caution against using the rim of the iceball seen on TRUS as an indicator of adequate cytodestruction. However, the importance of the present study is not in establishing a difference between a tumour temperature of more or less than −15°C, and indeed there were too few samples to determine statistical significance, but is the observation that more than half the tumours frozen to between 0°and −15°C had histological evidence of recurrence. These temperatures are not often reached at the posterior aspect of the prostate in man, where histological recurrences do occur. This may explain the high rate of positive transrectal biopsies after prostate cryosurgery seen in some series. 
